sibenadet has been researched along with Obstructive Lung Diseases in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bonnert, RV; Brown, RC; Chapman, D; Cheshire, DR; Davis, AM; Dixon, J; Dougall, IG; Hallam, C; Harper, ST; Ince, F; Jackson, DM; Kinchin, EC; Lyons, AJ; McKechnie, K; Simpson, WT; Unitt, JF; Young, A | 1 |
| Bayliss, MA; Gilbert, CM; Lockley, WJ; Mather, A; Singh, J; Wilkinson, D; Willson, VJ | 1 |
2 other study(ies) available for sibenadet and Obstructive Lung Diseases
| Article | Year |
|---|---|
Dual D2-receptor and beta2-adrenoceptor agonists for the treatment of airway diseases. 1. Discovery and biological evaluation of some 7-(2-aminoethyl)-4-hydroxybenzothiazol-2(3H)-one analogues.
Topics: Adrenergic beta-2 Receptor Agonists; Adrenergic beta-Agonists; Animals; Anti-Asthmatic Agents; Bronchoconstriction; Dogs; Dopamine Agonists; Drug Evaluation, Preclinical; Ear; In Vitro Techniques; Lung Diseases, Obstructive; Mucus; Rabbits; Receptors, Dopamine D2; Respiration; Thiazoles; Vasoconstriction | 1998 |
A time-resolved fluorescence immunoassay for the determination of a novel respiratory therapeutic agent, AR-C68397XX (Viozan) in human plasma.
Topics: Adrenergic beta-Agonists; Humans; Immunoassay; Lung Diseases, Obstructive; Reproducibility of Results; Thiazoles | 2000 |